



Curriculum Vitae

Personal information **Susanne Havn Aamand**

Work experience

1. Employer: Danish Medicines Agency
 - Start date: 012017
 - End date:
 - Position: Assessor of biologicals
 - Activities: Assessment of quality of biologicals
 - Country: Denmark
2. Employer: Statens Serum Institute
 - Start date: 082000
 - End date: 012017
 - Position: Chief Consultant
 - Activities: Production support, bacterial vaccines (tetanus, diphtheria, pertussis, BCG) and polio vaccine: Trouble shooting, process development, process optimisation, validation, quality issues, and regulatory requirements
 - Country: Denmark
3. Employer: University of Copenhagen
 - Start date: 061995
 - End date: 052000
 - Position: Post doc
 - Activities: Production and characterisation of antibiotics and enzymes by filamentous fungi
 - Country: Denmark
4. Employer: Technical University of Denmark
 - Start date: 031989
 - End date: 011991
 - Position: Research assistant
 - Activities: Isolation and characterisation of cellulases from strictly anaerobic fungi
 - Country: Denmark

Education and training

1. Subject: University of Copenhagen
 - Start date: 1991
 - End date: 1995
 - Qualification: Ph.D. Microbial physiology
 - Organisation: Regulation of penicillin biosynthesis by *Penicillium chrysogenum*
 - Country: Denmark
2. Subject: University of Copenhagen
 - Start date: 1988
 - End date: 1989
 - Qualification: MSc Biology
 - Organisation: Regulation of production of conidia, and onset of germination of conidia, in the thermophilic fungus *Thermomyces lanuginosus*
 - Country: Denmark

Additional information

Publications

Please note that my maiden name was S.H. Eriksen PUBLICATIONS: S. Biering_Sørensen, K.J. Jensen, S.H. Aamand, B. Blok, A. Andersen, I. Monteiro, M.G. Netea, P. Aaby, C.S. Benn, K.R. Hasløv (2015). Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial. *Vaccine* 17:2056_65 S. Arnesen, S.H. Eriksen, J. Olsen, B. Jensen (2002). De novo synthesis is involved in the production of extracellular alpha_amylase activity from *Thermomyces lanuginosus* in the stationary phase. *Mycol. Re.* 106:345_348 T. Aalbæk, M. Reeslev, B. Jensen, and S.H. Eriksen (2002). Acid protease and formation of multiple forms of glucoamylase in batch and continuous cultures of *Aspergillus niger*. *Enzyme and Microbial Technology* 30:410_415 C.W. Jürgensen, N.R. Jacobsen, T. Emri, S.H. Eriksen, I. Pócsi (2001). Glutathione metabolism and dimorphism in *Aurobasidium pullulans*. *J. Basic Microbiol.* 1:131_137 S.H. Eriksen, T.B. Søderblom, B. Jensen, and J. Olsen (1998). Uptake of phenylacetic acid by two different strains of *Penicillium chrysogenum*. *Biotechnol. Bioeng.* 60:310_316 S.H. Eriksen, B. Jensen, and J. Olsen (1998). Importance of glycosylation for secretion, activity, and stability of alpha_amylase from *Aspergillus niger*. *Curr. Microbiol.* 37:117_122 S. Arnesen, S.H. Eriksen, J. Olsen, and B. Jensen (1998). Increased production of alpha_amylase from *Thermomyces lanuginosus* by the addition of Tween 80. *Enzyme Microb. Technol.* 23:249_252 S.H. Eriksen, B. Jensen, I. Schneider, S. Kaasgaard, and J. Olsen (1995). Uptake of phenoxycetic acid by *Penicillium chrysogenum*. *Appl. Microbiol. Biotechnol.* 42:945_950 S.H. Eriksen, B. Jensen, I. Schneider, S. Kaasgaard, and J. Olsen (1994). Utilization of side_chain precursors for penicillin biosynthesis in a high producing strain of *Penicillium chrysogenum*. *Appl. Microbiol. Biotechnol.* 40:883_887 S.H. Eriksen, I. Haasum, B. Jensen, and J. Olsen (1992). Description of conidia from submerged cultivation of *Thermomyces lanuginosus* for use as a uniform inoculum. *FEMS Microbiol. Lett.* 93:279_284 I. Haasum, S.H. Eriksen, B. Jensen, and J. Olsen (1991). Growth and glucoamylase production by the thermophilic fungus *Thermomyces lanuginosus* in a synthetic medium. *Appl. Microbiol. Biotechnol.* 34:656_660

Projects

Memberships

Other Relevant Information

TRAINING FOR IMMUNOLOGICALS ASSESSORS: Quality of veterinary immunological products": 19_20 October 2017, EMA Regulatory Affairs Module 10, Biopharmaceuticals – Quality Development and Documentation Regulatory November 8_10, 2017, Atrium/University of Copenhagen